Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
BAX · against 1,336 other Healthcare companies
Ranked #783 of 1,337 · scores higher than 41% of peers
Bars: peers in each 10-point band of the valuation score134 peers with a valuation score of 40–49, including BAX · Click a bar to see the companies
A mix: stronger free cash flow yield and EBITDA yield, but weaker earnings yield than most Healthcare peers.
| Metric | BAX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | -7.6% | 1.5% | 23% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | 9.1% | 4.2% | 77% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | 6.2% | -1.0% | 84% | 20% | |
| Book yieldHigher is better · 1,306 reported | 47.1% | 37.9% | 60% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 783 | 8.8B CNY (≈$1.2B) | 41 | 54 | |
| 783 | 148M AUD (≈$98M) | 41 | 39 | |
| 783 | 7.7B USD | 41 | 37 | |
| 783 | 593.2B INR (≈$7.1B) | 41 | 47 | |
| 783 | 13.2B USD | 41 | 30 | |
| 783 | 10.8B USD | 41 | 41 | |
| 783 | 449M USD | 41 | 72 | |
| 783 | 12.6B USD | 41 | 65 | |
| 783 | 639M AUD (≈$422M) | 41 | 55 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score